About this trial
This clinical trial looks at how pancreatic cancer cells use nutrients to survive. Researchers want to understand the processes these tumors rely on, called metabolism. During surgery, participants will receive a special type of glucose. This will help doctors see how pancreatic cancer behaves compared to normal pancreatic cells in the lab.
The trial's ID number is NCT05296421. It is not currently in any specific phase, and it is not FDA-regulated. The goal is to include 16 participants.
Who can join
This study is open to men and women who are 18 years or older. Participants must have pancreatic adenocarcinoma that can be surgically removed. They should be willing to have biopsies taken during surgery. The trial includes 16 patients: 8 who have not had treatment and 8 who have had at least 3 months of chemotherapy. The trial team will confirm if someone is eligible to join.
Condition
Pancreatic Ductal Adenocarcinoma
Age group
Adult, Older adult
The study team makes the final call on eligibility.
What happens in the study
Participants will receive the special glucose through an IV during surgery. After that, they will have a biopsy and surgery as part of their normal care. Everyone in the trial will follow the same procedure to help researchers learn more about pancreatic cancer.
Where
This trial is running at 2 locations in the United States. All of them are currently recruiting.
Cooperman Barnabas Medical Center (Saint Barnabas Medical Center)
Livingston, New Jersey
Rutgers Cancer Institute of New Jersey
New Brunswick, New Jersey